BACKGROUND & AIMS: The goal of radiofrequency ablation (RFA) for patients with Barrett's esophagus (BE) is to eliminate dysplasia and metaplasia. The efficacy and safety of RFA for patients with BE and neoplasia are characterized incompletely. METHODS: We performed a retrospective study of 244 patients treated with RFA for BE with dysplasia or intramucosal carcinoma. Efficacy outcomes were complete eradication of intestinal metaplasia (CEIM), complete eradication of dysplasia, total treatments, and RFA sessions. Safety outcomes included death, perforation, stricture, bleeding, and hospitalization. We identified factors associated with incomplete EIM and stricture formation. RESULTS: CEIM was achieved in 80% of patients, and complete eradication of dysplasia was achieved in 87%; disease progressed in 4 patients. A higher percentage of patients with incomplete EIM were female (40%) than those with CEIM (20%; P = .045); patients with incomplete EIM also had a longer segment of BE (5.5 vs 4.0 cm; P = .03), had incomplete healing between treatment sessions (45% vs 15%; P = 0.004), and underwent more treatment sessions (4 vs 3; P = .007). Incomplete healing was associated independently with incomplete EIM. Twenty-three patients (9.4%) had a treatment-related complication during 777 treatment sessions (3.0%), including strictures (8.2%), postprocedural hemorrhages (1.6%), and hospitalizations (1.6%). Patients who developed strictures were more likely to use nonsteroidal anti-inflammatory drugs than those without strictures (70% vs 45%; P = .04), have undergone antireflux surgery (15% vs 3%; P = .04), or had erosive esophagitis (35% vs 12%; P = .01). CONCLUSIONS: RFA is highly effective and safe for treatment of BE with dysplasia or early stage cancer. Strictures were the most common complications. Incomplete healing between treatment sessions was associated with incomplete EIM. Nonsteroidal anti-inflammatory drug use, prior antireflux surgery, and a history of erosive esophagitis predicted stricture formation.
BACKGROUND & AIMS: The goal of radiofrequency ablation (RFA) for patients with Barrett's esophagus (BE) is to eliminate dysplasia and metaplasia. The efficacy and safety of RFA for patients with BE and neoplasia are characterized incompletely. METHODS: We performed a retrospective study of 244 patients treated with RFA for BE with dysplasia or intramucosal carcinoma. Efficacy outcomes were complete eradication of intestinal metaplasia (CEIM), complete eradication of dysplasia, total treatments, and RFA sessions. Safety outcomes included death, perforation, stricture, bleeding, and hospitalization. We identified factors associated with incomplete EIM and stricture formation. RESULTS:CEIM was achieved in 80% of patients, and complete eradication of dysplasia was achieved in 87%; disease progressed in 4 patients. A higher percentage of patients with incomplete EIM were female (40%) than those with CEIM (20%; P = .045); patients with incomplete EIM also had a longer segment of BE (5.5 vs 4.0 cm; P = .03), had incomplete healing between treatment sessions (45% vs 15%; P = 0.004), and underwent more treatment sessions (4 vs 3; P = .007). Incomplete healing was associated independently with incomplete EIM. Twenty-three patients (9.4%) had a treatment-related complication during 777 treatment sessions (3.0%), including strictures (8.2%), postprocedural hemorrhages (1.6%), and hospitalizations (1.6%). Patients who developed strictures were more likely to use nonsteroidal anti-inflammatory drugs than those without strictures (70% vs 45%; P = .04), have undergone antireflux surgery (15% vs 3%; P = .04), or had erosive esophagitis (35% vs 12%; P = .01). CONCLUSIONS: RFA is highly effective and safe for treatment of BE with dysplasia or early stage cancer. Strictures were the most common complications. Incomplete healing between treatment sessions was associated with incomplete EIM. Nonsteroidal anti-inflammatory drug use, prior antireflux surgery, and a history of erosive esophagitis predicted stricture formation.
Authors: Nicholas J Shaheen; Bergein F Overholt; Richard E Sampliner; Herbert C Wolfsen; Kenneth K Wang; David E Fleischer; Virender K Sharma; Glenn M Eisen; M Brian Fennerty; John G Hunter; Mary P Bronner; John R Goldblum; Ana E Bennett; Hiroshi Mashimo; Richard I Rothstein; Stuart R Gordon; Steven A Edmundowicz; Ryan D Madanick; Anne F Peery; V Raman Muthusamy; Kenneth J Chang; Michael B Kimmey; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; John A Dumot; Gary W Falk; Joseph A Galanko; Blair A Jobe; Robert H Hawes; Brenda J Hoffman; Prateek Sharma; Amitabh Chak; Charles J Lightdale Journal: Gastroenterology Date: 2011-05-06 Impact factor: 22.682
Authors: Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen Journal: Gastroenterology Date: 2011-03 Impact factor: 22.682
Authors: Ngozi I Okoro; Yutaka Tomizawa; Kelly T Dunagan; Lori S Lutzke; Kenneth K Wang; Ganapathy A Prasad Journal: Clin Gastroenterol Hepatol Date: 2011-11-02 Impact factor: 11.382
Authors: Virender K Sharma; H Jae Kim; Ananya Das; Christopher D Wells; Cuong C Nguyen; David E Fleischer Journal: Am J Gastroenterol Date: 2009-01-27 Impact factor: 10.864
Authors: Roos E Pouw; Katja Wirths; Pierre Eisendrath; Carine M Sondermeijer; Fiebo J Ten Kate; Paul Fockens; Jacques Devière; Horst Neuhaus; Jacques J Bergman Journal: Clin Gastroenterol Hepatol Date: 2009-08-11 Impact factor: 11.382
Authors: Robert A Ganz; Bergein F Overholt; Virender K Sharma; David E Fleischer; Nicholas J Shaheen; Charles J Lightdale; Stephen R Freeman; Ronald E Pruitt; Shiro M Urayama; Frank Gress; Darren A Pavey; M Stanley Branch; Thomas J Savides; Kenneth J Chang; V Raman Muthusamy; Anthony G Bohorfoush; Samuel C Pace; Steven R DeMeester; Viktor E Eysselein; Masoud Panjehpour; George Triadafilopoulos Journal: Gastrointest Endosc Date: 2008-03-19 Impact factor: 9.427
Authors: Sarina Pasricha; Nan Li; William J Bulsiewicz; Richard I Rothstein; Anthony Infantolino; Atilla Ertan; Daniel S Camara; Evan S Dellon; George Triadafilopoulos; Charles J Lightdale; Ryan D Madanick; William D Lyday; Raman V Muthusamy; Bergein F Overholt; Nicholas J Shaheen Journal: Gastrointest Endosc Date: 2015-04-01 Impact factor: 9.427
Authors: Adam C Strauss; Agoston T Agoston; Parambir S Dulai; Amitabh Srivastava; Richard I Rothstein Journal: Surg Endosc Date: 2014-12 Impact factor: 4.584
Authors: Rebecca J Critchley-Thorne; Lucas C Duits; Jeffrey W Prichard; Jon M Davison; Blair A Jobe; Bruce B Campbell; Yi Zhang; Kathleen A Repa; Lia M Reese; Jinhong Li; David L Diehl; Nirag C Jhala; Gregory Ginsberg; Maureen DeMarshall; Tyler Foxwell; Ali H Zaidi; D Lansing Taylor; Anil K Rustgi; Jacques J G H M Bergman; Gary W Falk Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-05-13 Impact factor: 4.254
Authors: Margriet R Timmer; Shannon M Brankley; Emmanuel C Gorospe; Gang Sun; Lori S Lutzke; Prasad G Iyer; Kevin C Halling; Kausilia K Krishnadath; Kenneth K Wang Journal: Gastrointest Endosc Date: 2014-07-29 Impact factor: 9.427